Federal Notice: AndersonBrecon, Inc. DBA PCI Pharma Services Applies To Import LSD For Clinical Trials Estimated reading time: 3–5 minutes On January 8, 2026, the United States Drug Enforcement Administration (DEA) announced a new application from AndersonBrecon, Inc. DBA PCI Pharma Services. The company, based at 5775 Logistics Parkway, Rockford, Illinois 61109-3608, has requested permission to import a controlled substance. The controlled substance is lysergic acid diethylamide, also known as LSD. The drug code for LSD is 7315. LSD is classified by the government as a Schedule I drug. AndersonBrecon, Inc. wants to import LSD only for use in clinical trials. No other activities with LSD are allowed under this application. The company is not allowed to import FDA-approved or non-approved finished dosage forms for commercial sale. The DEA states that approval for importing will only happen if the company’s activities match what is allowed under United States law, specifically 21 U.S.C. 952(a)(2). Other companies or people who already make or use LSD in bulk can send comments or objections to the proposed registration. They may also request a hearing. All comments or hearing requests must be submitted by February 9, 2026. Comments should be sent through the Federal eRulemaking Portal at https://www.regulations.gov. For hearings, requests must be sent to: Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152 Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152 Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152 The DEA notice was signed by Thomas Prevoznik, Deputy Assistant Administrator. This public notice appears in the Federal Register, Volume 91, Number 5, on January 8, 2026, pages 724-725. The docket number is DEA-1638. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Notice: Janssen Pharmaceuticals Applies to Import Controlled Substances Estimated reading time: 2–3 minutes Date: January 8, 2026 Who applied: Janssen Pharmaceuticals Inc. applied to be registered as an importer of specific controlled substances. Address: 1440 Olympic Drive, Buildings 1-5 & 7-14, Athens, Georgia 30601-1645. Controlled Substances Requested: Ethylphenidate (Drug code: 1727, Schedule I) Methylphenidate (Drug code: 1724, Schedule II) Purpose: Janssen plans to import these substances only for analytical purposes. No other activities involving these drug codes are permitted under this registration. Regulatory Information: The application follows 21 CFR 1301.34(a). Permit approvals will happen only if the business activity fits U.S. law, specifically 21 U.S.C. 952(a)(2). The permission does not allow the import of finished drugs, whether FDA-approved or not, for sale. Comments and Hearings: Registered bulk manufacturers and applicants can submit electronic comments or objections by February 9, 2026. Requests for a hearing about the application must be submitted by February 9, 2026. Comments must be made at https://www.regulations.gov. Hearing requests must be sent to the DEA at 8701 Morrissette Drive, Springfield, Virginia 22152, to the Attention of the Hearing Clerk/OALJ, DEA Federal Register Representative/DPW, and the Administrator. Notice Published By: Thomas Prevoznik, Deputy Assistant Administrator. Document Number: 2026-00128 Date Filed: January 7, 2026 For more information, visit the official Federal Register website. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Curium US LLC Applies to Import Controlled Substance Estimated reading time: 2–4 minutes Curium US LLC has applied to become an importer of a controlled substance. This information was released by the Drug Enforcement Administration (DEA) in a notice published on January 8, 2026. The application is for importing a substance called ecgonine. The drug code for ecgonine is 9180. Ecgonine is listed as a Schedule II controlled substance. Curium US LLC is located at 2703 Wagner Place, Maryland Heights, Missouri 63043-3421. The company wants to import small amounts of a derivative form of ecgonine. The purpose is to use the substance for manufacturing. No other activities for this drug code are allowed under this registration. Anyone interested in this proposed registration can send a comment or objection. Comments must be submitted electronically through the Federal eRulemaking Portal at https://www.regulations.gov. The deadline to submit comments or requests for a hearing is February 9, 2026. People who want a hearing need to send their request to the DEA at 8701 Morrissette Drive, Springfield, Virginia 22152. The DEA will approve permit applications only if they fit the rules described in 21 U.S.C. 952(a)(2). The authorization does not allow for importing finished dosage forms, whether they are approved or not by the Food and Drug Administration (FDA), for commercial sale. The notice was signed by Thomas Prevoznik, Deputy Assistant Administrator at the DEA. For more information, see the notice published in the Federal Register Volume 91, Number 5, on January 8, 2026. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Mylan Technologies Applies to Import Controlled Substances for Testing Estimated reading time: 2–3 minutes Mylan Technologies Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of controlled substances. The application was officially filed on October 7, 2025. Mylan Technologies is located at 110 Lake Street, Saint Albans, Vermont 05478-2266. The company seeks to import two specific controlled substances. These are: Methylphenidate (Drug code 1724, Schedule II) Fentanyl (Drug code 9801, Schedule II) Mylan plans to import these substances in finished dosage form (FDF) from foreign sources. The imports will be used for analytical testing and clinical trials. In these trials, the foreign FDF will be compared to the company’s own FDF made in the United States for foreign markets. The registration does not authorize other activities for these drug codes. The permit is only for testing and trials. It does not allow the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. The DEA will grant approval only if the registrant’s activities match what is allowed under U.S. law. Other uses are not permitted. People who make these substances or want to make them may submit comments or objections. Comments must be sent electronically by February 9, 2026. Written requests for a hearing on the application must also be sent by this date. Comments must be submitted through the Federal eRulemaking Portal at regulations.gov. Written hearing requests must be sent to: 1. Drug Enforcement Administration, Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152 2. Drug Enforcement Administration, DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152 3. Drug Enforcement Administration, Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152 This notice follows 21 CFR 1301.34(a), which governs the importation of controlled substances. The announcement was issued by Thomas Prevoznik, Deputy Assistant Administrator of the DEA. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Fifth Religious Liberty Commission Meeting Estimated reading time: 3-5 minutes The United States Department of Justice (DOJ) has announced the fifth meeting of the Religious Liberty Commission. The meeting will take place on February 9, 2026, from 8:30 a.m. to 2:30 p.m. The location will be the World Stage Theatre at the Museum of the Bible in Washington, DC. The meeting will also be recorded and broadcast online at justice.gov/live. The Religious Liberty Commission is a federal advisory committee. It was established by the President through Executive Order 14291. The Commission has a chair, a vice chair, and eleven members appointed by the President. Members include people from the private sector, employers, educational institutions, religious communities, States, and three ex-officio members. The Commission gives advice to the Domestic Policy Council and the White House Faith Office. They focus on religious liberty policies in the United States. The Commission will create a detailed report for the President. This report will cover the foundations of religious liberty in America, the impact of religious liberty on American society, current threats to religious liberty in the country, strategies to protect religious liberty for the future, and programs to teach about and support America’s peaceful religious diversity. At the February 9, 2026 meeting, the Commission will discuss religious liberty issues related to anti-Semitism. They will also talk about religious liberty issues in the private sector. The meeting is open to the public. People who want to attend in person must register. Registration is available on the Religious Liberty Commission website at https://www.justice.gov/religious-liberty-commission. Attendance is limited to the number of seats at the venue. All in-person attendees will need to show identification and go through security screening. Media members must register through the Office of Public Affairs by February 5, 2026, at 5 p.m. They must also bring government-issued photo identification and valid media credentials and go through security checks. Anyone can send written comments to the Commission. Comments can be emailed to the contact address listed or sent by mail to the U.S. Department of Justice, Office of the Associate Attorney General, ATTN: Religious Liberty Commission, 950 Pennsylvania Avenue NW, Room 5706, Washington, DC 20530. The deadline for comments is February 1, 2026. For more information or to request a reasonable accommodation to attend, contact Mary Margaret Bush, Director and Designated Federal Officer for the Religious Liberty Commission, at the Department of Justice. The notice of this meeting is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 et seq.). Dated: January 6, 2026.Mary Margaret BushDesignated Federal Officer, Religious Liberty Commission Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Sixth Religious Liberty Commission Meeting Estimated reading time: 4–5 minutes The United States Department of Justice has announced the sixth Federal advisory committee meeting of the Religious Liberty Commission. The meeting will be open to the public. It is scheduled for March 16, 2026, from 8:30 a.m. to 2:30 p.m. The meeting will take place at the World Stage Theatre at the Museum of the Bible in Washington, DC. The meeting will be recorded and broadcast live online at justice.gov/live. To attend the meeting in person, registration is required. Attendance is limited by the venue’s capacity. People can register on the Religious Liberty Commission website at here. All attendees must bring identification and go through security. Media guests must register with the Department of Justice Office of Public Affairs by March 12, 2026, at 5 p.m. Media should have government-issued photo I.D. and valid media credentials. Mary Margaret Bush is the Director of the Religious Liberty Commission and serves as the Designated Federal Officer. She can be reached by email or phone at 202-514-2046. She can also help people who need a reasonable accommodation to attend. The Religious Liberty Commission was set up by the President through Executive Order 14291. It has a chair, a vice chair, and eleven members chosen by the President. Members include people from the private sector, states, educational institutions, religious communities, and three ex-officio members. The Commission gives advice to the Domestic Policy Council and the White House Faith Office on religious liberty policies. It will prepare a report to the President. This report will cover the foundations of religious liberty in America, its impact on society, current threats, ways to protect religious liberty for future generations, and programs to celebrate America’s religious diversity. The agenda for the March 16 meeting will focus on religious liberty issues related to healthcare and humanitarian and social services. People can send in written comments by email or mail. The deadline for comments is March 8, 2026. Comments can be emailed or mailed to the U.S. Department of Justice, Office of the Associate Attorney General, Religious Liberty Commission, 950 Pennsylvania Avenue NW, Room 5706 Washington, DC 20530. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. 1001 et seq.). The notice was signed by Mary Margaret Bush, Designated Federal Officer, Religious Liberty Commission, on January 6, 2026. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Kinetochem LLC Applies to Make Controlled Substances in Bulk Estimated reading time: 2–3 minutes On December 3, 2025, the Drug Enforcement Administration (DEA) announced that Kinetochem LLC has applied to be registered as a bulk manufacturer for several controlled substances. The notice was published in the Federal Register, Volume 90, Number 230. Kinetochem LLC is located at 96 Market Street, Suite 102, Georgetown, Texas, 78626-3618. The company applied on October 15, 2025. The application is for these controlled substances: Marihuana (drug code 7360, Schedule I) Tetrahydrocannabinols (drug code 7370, Schedule I) Psilocybin (drug code 7437, Schedule I) Psilocyn (drug code 7438, Schedule I) Kinetochem LLC plans to make these controlled substances in bulk. They will make them as Active Pharmaceutical Ingredients (APIs) for use by customers. The substances will also be used for research and clinical trials. For marihuana and tetrahydrocannabinols, the company will manufacture only synthetic versions. No other activities are allowed for these drug codes with this registration. Anyone who is a registered bulk manufacturer of the affected substances, or is applying to be one, can submit comments or objections to the DEA by February 2, 2026. They can also ask for a hearing by that date. Comments can be submitted electronically at https://www.regulations.gov. After submitting, the commenter will receive a Comment Tracking Number. Comments will not appear on the website right away. This information was provided by Thomas Prevoznik, the Deputy Assistant Administrator of the DEA. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Seeks Comments on COPS Progress Report Collection Estimated reading time: 3–5 minutes On December 3, 2025, the Department of Justice (DOJ) published a notice in the Federal Register. The notice is about the COPS Progress Report information collection. COPS stands for Community Oriented Policing Services. The DOJ wants public comments for 60 days, until February 2, 2026. The goal is to get feedback about collecting information from state, local, and tribal governments. The notice asks people to answer these questions: Is the collection needed for the Bureau of Justice Statistics to work well? Is the DOJ’s estimate of how much work it will take correct? Can the information collected be clearer and more useful? How can the work for people responding be made easier, such as using electronic forms? Here is an overview of this information collection: Type of Collection: Extension of a previously approved collection. Form Name: COPS Progress Report. Form Number: OMB #1105-0102. DOJ section: COPS. Who Responds: State, Local, and Tribal Governments. Obligation: Mandatory. Respondents: About 4,800 groups. Time Needed per Respondent: 25 minutes. How Often: Four times per year (semi-annually). Total Annual Hours Needed: 600 hours. Estimated Annual Cost: $12,000, based on $20 per hour. If you want more details or need the forms, contact Cory D. Randolph at the Office of Community Oriented Policing Services, Two Constitution Square, 145 N Street NE, Washington, DC 20530. If more information is needed, contact Darwin Arceo, Department Clearance Officer, United States Department of Justice, Justice Management Division, Enterprise Portfolio Management, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC. The notice was signed by Darwin Arceo on December 1, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Blue Rabbit Veterinary LLC Applies to Import Controlled Substances Estimated reading time: 1 minute Blue Rabbit Veterinary LLC has applied to be registered as an importer of controlled substances. The application was filed with the Drug Enforcement Administration (DEA), Department of Justice. The company is located at 1680 East Northrop Boulevard, Unit 1, Chandler, Arizona 85286. Blue Rabbit Veterinary LLC seeks to import two controlled substances: Etorphine HCI (Drug code: 9059), Schedule II Thiafentanil (Drug code: 9729), Schedule II The purpose of the import is to distribute the drugs in final dosage form to zoo and wildlife customers. No other activities with these drug codes are allowed for this registration. The notice came in the Federal Register, Volume 90, Number 228, on December 1, 2025. Registered bulk manufacturers and applicants can send objections or comments by December 31, 2025. All comments must be submitted electronically through https://www.regulations.gov. People who want a hearing must send their request to the DEA at 8701 Morrissette Drive, Springfield, Virginia 22152. The DEA will approve permit applications only when the business activity matches what is authorized under 21 U.S.C. 952(a)(2). Authorization will not allow the import of FDA-approved or non-approved finished dosage forms for commercial sale. The notice was signed by Thomas Prevoznik, Deputy Assistant Administrator for the DEA. For more information, refer to Federal Register notice 2025-21719. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Benuvia Operations, LLC Applies to Manufacture Controlled Substances Estimated reading time: 1–4 minutes The Drug Enforcement Administration (DEA) announced that Benuvia Operations, LLC has applied to be a bulk manufacturer of certain controlled substances. The company is located at 3950 North Mays Street, Round Rock, Texas 78665. Benuvia Operations, LLC applied on October 27, 2025. The application is for the following drugs: Lysergic Acid Diethylamide (Drug code: 7315) – Schedule I Codeine (Drug code: 9050) – Schedule II Hydromorphone (Drug code: 9150) – Schedule II Sufentanil (Drug code: 9740) – Schedule II The company wants to make these drugs in bulk. The purpose is for internal research and for making new dosage forms. No other activities are allowed for these drugs under this registration. If other manufacturers or applicants are affected by this notice, they can comment on the application. They must submit their comments electronically by January 30, 2026. Comments must be sent through the Federal eRulemaking Portal at https://www.regulations.gov. Anyone who wants a hearing on this application must also submit a written request by January 30, 2026. Thomas Prevoznik, the Deputy Assistant Administrator, signed this notice. This notice was published in the Federal Register, Volume 90, Number 228, on Monday, December 1, 2025. The document number is 2025-21720. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Invizyne Technologies Applies to Make Controlled Substances Estimated reading time: 1–4 minutes On December 1, 2025, the Drug Enforcement Administration (DEA) published a notice in the Federal Register about Invizyne Technologies, Inc. The notice says that Invizyne Technologies has applied to be a bulk manufacturer of a controlled substance. Invizyne Technologies is based at 750 Royal Oaks Drive, Suite 106, Monrovia, California, 91016-6357. The company wants to make large amounts of a substance called Tetrahydrocannabinols. The drug code for Tetrahydrocannabinols is 7370. It belongs to Schedule I of controlled substances. The company wants to make this substance as a synthetic version. They plan to use it either for making other materials inside their company or to sell it to their customers. This is the only activity allowed for this drug code under this registration. People who are already registered to make bulk amounts of this kind of drug, and people who want to register, can send comments or objections to the DEA. They must do this by January 30, 2026. Anyone who wants to have a hearing about this application has to ask for it by January 30, 2026. All comments need to be sent in electronically through the Federal eRulemaking Portal at https://www.regulations.gov. After sending a comment, people will get a Comment Tracking Number. The comment might not show up on the website right away. The notice was signed by Thomas Prevoznik, Deputy Assistant Administrator at the DEA. This notice is part of the government’s process to let the public know and ask for input when a company applies to make a controlled substance in bulk. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Proposed Changes to Juvenile Facility Census Program Estimated reading time: 3–5 minutes The Department of Justice (DOJ) has published a notice about a planned update to its Juvenile Facility Census Program (JFCP). This program collects information about places where young people under age 21 are kept because of contact with the justice system. The update has been sent to the Office of Management and Budget (OMB) for review and approval. Public Comments Invited People can comment on the changes until December 29, 2025. The DOJ wants feedback about whether the update is needed, if the time estimates are right, ideas for making the questions better, and ways to lower the time or work required. Comments can be sent through www.reginfo.gov/public/do/PRAMain online. Details of the Census Program The JFCP is a combination of two earlier data collections: the Census of Juveniles in Residential Placement (CJRP) and the Juvenile Residential Facility Census (JRFC). Now, instead of doing these separately, they will be merged into one program. The census collects details from all types of youth residential facilities—both secure and nonsecure. These include places where youth are housed for law violations, whether they are waiting for court or have been committed after being found responsible for an offense. There are two main parts to the new program. The first is the Youth Population module. It asks for details about the youth living in the facilities, including their ages, backgrounds, and the length of time they stay. The second is the Facility Operations module. This part covers information about the services, features, and daily operations of each facility. Each of these two modules is collected separately during a two-year cycle. Number of Respondents and Time Required About 1,636 people or groups will need to respond for each module each year. It takes about 4 hours to complete the Youth Characteristics (CJ-14) module and 2 hours for the Facility Operations (CJ-15) module. The total work time for everyone for one full collection cycle will be about 9,816 hours. Costs of the Program The DOJ says the yearly cost of collecting this information is about $1,142,115. For the full two-year cycle, the cost is estimated at $2,284,230. Why the Change? By combining the two separate data collections into one, the DOJ hopes to save money and reduce the amount of work for people who have to answer the questions. When Will It Happen? The DOJ is asking for approval to run this information collection system for two years at a time. Each approval from OMB cannot last longer than three years without another review. How to Get More Information If you need more information about this update, you can contact Benjamin Adams, Supervisory Social Science Analyst, at the National Institute of Justice, by email or phone. You may also reach Darwin Arceo, the Department Clearance Officer, at the Department of Justice in Washington, DC. This notice was signed by Darwin Arceo on November 25, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Seeks Public Comments on Juvenile Facility Census Program Estimated reading time: 3–5 minutes The Department of Justice (DOJ) has announced a plan to revise and combine two data collections into one program called the Juvenile Facility Census Program (JFCP). The plan is published in the Federal Register on November 28, 2025. The DOJ is asking for public comments for 30 days, ending December 29, 2025. The JFCP is overseen by the National Institute of Justice and the Office of Juvenile Justice and Delinquency Prevention. The program collects information from all types of facilities that house young people under 21 years old after contact with the juvenile justice system. This includes youth held for status offenses and delinquency offenses. The JFCP will replace two earlier programs: Census of Juveniles in Residential Placement (CJRP) Juvenile Residential Facility Census (JRFC) The program gathers general information about each facility and counts of youth who live there. There are two main sections, called modules: Youth Characteristics Module (Form CJ-14): This asks for details about each youth, like age, gender, and how long they stay in a facility. It takes about 4 hours to finish for each facility. Facility Operations Module (Form CJ-15): This collects information on services, features, and how the facility works. It takes about 2 hours to finish for each facility. The JFCP works on a two-year cycle. Each year, both modules are given to about 1,636 facilities. Each cycle totals about 9,816 hours of work for everyone, split between the two modules. The Youth Characteristics module takes 6,544 total hours. The Facility Operations module takes 3,272 hours. The information collected helps create reports and statistics. These materials are shared with Congress, the President’s office, researchers, media, and the public through agency websites. Responding to the survey is voluntary. Estimated annual costs for the JFCP are $1,142,115, with each full collection cycle costing $2,284,230. Anyone who wants to see the forms or comment on the program can visit www.reginfo.gov/public/do/PRAMain. Comments can include thoughts on the need for the collection, how useful the data are, accuracy of the burden estimates, ways to improve the questions, or ways to reduce the burden. For questions, contact Benjamin Adams, Supervisory Social Science Analyst, National Institute of Justice, 999 North Capitol Street NE, Washington, DC 20531, email: [protected], phone: 202-598-6493. For more facts, contact Darwin Arceo, Department Clearance Officer, Justice Management Division, U.S. Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC 20530. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Places 4-Chloromethcathinone (4-CMC) in Schedule I of the Controlled Substances Act Estimated reading time: 4–6 minutes On November 17, 2025, the Drug Enforcement Administration (DEA) published a final rule in the Federal Register. This rule adds 4-Chloromethcathinone (also known as 4-CMC, 1-(4-chlorophenyl)-2-(methylamino)propan-1-one) to Schedule I of the Controlled Substances Act (CSA). 4-CMC and its salts, isomers, and salts of isomers will now be subject to the same strict rules as other Schedule I drugs. Why Is 4-CMC Being Scheduled? The United States is part of an international agreement called the 1971 Convention on Psychotropic Substances. This agreement asks countries to control certain drugs that might be abused. The United Nations Commission on Narcotic Drugs made a decision in 2020 to control 4-CMC. The U.S. must now control it too. The Department of Health and Human Services (HHS) and the DEA both did reports on 4-CMC. They reviewed scientific and medical information and decided 4-CMC should be placed in Schedule I. What Is 4-CMC? 4-CMC is a central nervous system stimulant. It is similar to other drugs like amphetamine, methamphetamine, and synthetic cathinones (such as 4-MEC and 4-FMC). What Does Schedule I Mean? Drugs in Schedule I: Have a high potential for abuse. Have no currently accepted medical use in the United States. Lack safe use even under medical supervision. HHS confirmed that 4-CMC has no medical use and is not an approved medicine. No healthcare experts in the U.S. accept it for treatment. There is not enough information about its safety. Public Comments When the DEA first announced this idea, people could give comments or ask for a hearing. One person commented against the scheduling, saying it could stop possible medical research. DEA replied that placing 4-CMC in Schedule I does not stop research. Researchers can apply for special permission to study Schedule I drugs. Rules for Handling 4-CMC Starting December 17, 2025: Anyone who makes, sells, gives out, imports, exports, studies, uses, or owns 4-CMC must register with the DEA. Anyone who does not register cannot handle 4-CMC. People who have 4-CMC but do not want to register must give their 4-CMC to someone registered or dispose of it properly. 4-CMC must be stored safely according to strict rules. Labels and packaging must follow the law. Only certain manufacturers can make 4-CMC, and they need DEA-approved quotas. DEA registrants must keep records and take inventories of 4-CMC. Reports must be sent to the DEA as required. Special order forms are needed to distribute 4-CMC. All importing and exporting 4-CMC must follow DEA regulations. Doing anything not allowed by DEA rules is illegal and can lead to punishment. Other Information This rule will not have a big economic effect on small businesses. There are no major government costs or big paperwork burdens. The rule will not change relationships between the U.S. government and state, local, or tribal governments. Listed in the Federal Register 4-CMC is now officially listed in Schedule I as follows:“4-Chloromethcathinone (4-CMC, 1-(4-chlorophenyl)-2-(methylamino)propan-1-one)” with code number 1239. Key Dates Rule published: November 17, 2025 Effective date: December 17, 2025 Contact for Questions Dr. Terrence L. BoosDrug and Chemical Evaluation SectionDiversion Control Division, DEATelephone: (571) 362-3249 Signed by:Terrance Cole, Administrator, DEAHeather Achbach, Federal Register Liaison Officer, DEA Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

ATF Proposes Revisions to Form 1: Application to Make and Register NFA Firearm Estimated reading time: 5–8 minutes On October 30, 2025, the Department of Justice (DOJ) and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) announced proposed changes to the information collection process for ATF Form 5320.1, also called “Form 1.” Form 1 is the document people use to apply to make and register a National Firearms Act (NFA) firearm. Public Comment Period Open The ATF is accepting written public comments for 30 days, until midnight on December 1, 2025. Comments should be submitted online at www.reginfo.gov/public/do/PRAMain. People can search for this collection using the title or OMB control number 1140-0015. What is Changing? ATF is revising Form 1 for several reasons: The number of applicants has increased. There are now an estimated 148,975 applicants, up from 25,716. The time to complete the form is now less. Better technology means fewer people need to provide fingerprints and photos, and electronic systems have made the process faster. Only one copy of the form needs to be filled out. You do not need to send an extra copy to local law enforcement anymore. Detailed Form Updates The title of the form is being revised to be clearer. The photo box is being removed. Now you can attach either a passport-style photo or a copy of a photo ID document. Race and ethnicity questions are being combined. More types of electronic and digital signatures will be allowed. The fillable PDF will now link copy 1 and copy 2, except for the checkboxes and signature. References to eForms (electronic forms) and Pay.gov are being added. The form will now include instructions on how to get a refund. The requirement to notify Chief Law Enforcement Officers (CLEOs) and submit an extra copy has been removed. Married couples jointly making, transferring, or registering a firearm will get new instructions, as an ‘other legal entity.’ Minor grammar mistakes are being fixed. There will be email addresses for questions about the form. Changes to the Tax Requirement Item 1a: Applicants must submit a $200 tax payment for each machinegun or destructive device. The tax can be paid by card, check, money order, or through Pay.gov. Item 1b: For other types of firearms, the tax is $0, and item 19 does not need to be completed. Impact on Applicants The estimated time per respondent is now 12 minutes, down from 30 minutes. The total annual time burden for all applicants is now 29,795 hours. The total estimated annual cost burden (excluding time) is $685,285. Comments and ATF Response One dealer supported removing the requirement to send a copy to CLEOs, saying this prevents CLEOs from accidentally creating a firearms registry. The commenter supported digital signatures and using copies of photo IDs, rather than photographs and fingerprints. ATF replied that the changes reflect a broader move to modernize and digitize NFA forms. The agency expects to move to online-only forms in 2026. Where to Get More Information For questions or copies of the documents, contact Meghan Tisserand at the National Firearms Act Division (304-616-3219) or Darwin Arceo at the Department of Justice. Summary ATF’s changes to Form 1 are designed to make the process of applying to make and register NFA firearms faster, easier, and more modern, with less paperwork and more digital options. Public comments are welcome until December 1, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

ATF Announces Big Changes to NFA Firearm Transfer Form (Form 4) Estimated reading time: 4–6 minutes The Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) is making big changes to Form 5320.4, also called “Form 4.” This is the form you use to transfer and register National Firearms Act (NFA) guns. These changes will help make the form easier and faster to fill out. The ATF is asking people to send in comments about these changes by December 1, 2025. Comments can be submitted online at www.reginfo.gov/public/do/PRAMain by searching for “Application To Transfer and Register NFA Firearm (Tax-Paid)” or the OMB control number “1140-0014”. Who is Affected? This information collection affects state, local, and tribal governments, individuals and families, private businesses, and even the federal government. People with NFA firearms have to apply to the ATF for approval to transfer or register their firearm using Form 4. The approved Form 4 is proof that the gun is legally registered. Important Changes to Form 4 The number of people filling out this form has gone up a lot, from 123,339 last time to 546,424 now. The average time to finish the form is now just 12 minutes, down from 30 minutes. Many steps can now be done electronically. This lets people use digital fingerprints, digital signatures, photos from cell phones, and photocopies of IDs. The extra requirement to send a copy of the form to local law enforcement (CLEO) is being removed. The online fillable form now makes a second copy automatically. The estimated total time people will spend on this a year is now 109,285 hours, which is much less than before. The estimated total other annual costs will be $2,513,555. Updates to the Tax Section The $5 transfer tax box in Item 1 has been removed and replaced with a $0 box. The instructions now state: “The transfer tax is $200.00 for machineguns and destructive devices. The transfer tax is $0.00 for other types of firearms.” Other Major Form Revisions The title of the form is now clearer. The photo box has been removed. People can now use either a passport-style photo or a copy of a photo ID. Race and ethnicity items are now combined. More types of digital signatures can be used. The fillable online form now links copy 1 and 2, so both are filled out at the same time. New references to eForms and pay.gov have been added. There are instructions for getting a refund. The CLEO notification and extra copy are removed. There are now instructions for married couples filling out the form together as a legal entity. There are email addresses for help with different questions. Typographical and grammar corrections have been made. Public and ATF Feedback One NFA firearms dealer submitted a comment. This person supported the changes. They liked the removal of the CLEO copy requirement and the push for more digital options. They said digital signatures and allowing a photo of a photo ID or cell phone photo made things easier. ATF said they value feedback. They explained they are moving all NFA forms to electronic options. Full online submissions are planned for 2026. Other NFA forms are also getting updated. For More Information Contact Darwin Arceo, Department Clearance Officer, U.S. Department of Justice, 145 N Street NE, Suite 4W-218, Washington, DC 20530. You can also contact Meghan Tisserand at the National Firearms Act Division for more help. Deadline If you have thoughts about these changes, you must submit your comments by December 1, 2025. Visit www.reginfo.gov for more details. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

ATF Announces Changes to NFA Firearm Transfer Form (Form 5) Estimated reading time: 5–7 minutes On October 30, 2025, the Department of Justice’s Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) published a notice in the Federal Register. The notice details proposed changes to the Application To Transfer and Register NFA Firearm (Tax-Exempt), also known as ATF Form 5320.5, or Form 5. The Form and Its Purpose Form 5 is used by people who need permission to transfer and register certain firearms covered under the National Firearms Act (NFA). Sometimes, these transfers do not need a tax because of special tax exemptions. People use Form 5 to claim these exemptions. ATF uses the form to check if the transfer is legal under federal, state, and local law. Some examples of use: Transferring a firearm from an estate to a beneficiary. Transferring firearms due to bankruptcy. Temporarily transferring firearms for repair and return. Who Uses the Form? The affected public includes: Federal, state, and local government agencies. People selling unserviceable firearms. Required Information To use the form, applicants need: To provide information about themselves and the firearm. If claiming a tax exemption, to give information supporting the claim. Why Is This Important? ATF is revising this information collection for several reasons: Respondents increased from 10,591 to 17,322 over three years. Time to complete the form dropped from 30 to 12 minutes. Improvements in technology allow more of the process to be done online or electronically. Fewer people must provide fingerprints or photographs. It is now easier to use cell phone photos or photocopied IDs. Copies of the form can be filled at the same time. The requirement to send an extra copy to local law enforcement is going away. The total time burden for all users dropped by 1,866 hours. The yearly total burden is now about 3,464 hours. The estimated yearly cost is $79,672. Changes to Form 5 Some changes include: A clearer title for the form. No more photo box; applicants can attach a photo or a copy of photo ID. Race and ethnicity items are now combined. More electronic and digital signature types are allowed. The form will automatically fill in copy 2 as copy 1 is completed. References to eForms and pay.gov have been added. Instructions for the refund process are included. The CLEO (Chief Law Enforcement Officer) notification requirement and copy are removed. New instructions for married couples applying together as a legal entity. Grammar and typo corrections. Email addresses for help and questions are added. Public Comments and ATF Response One firearm dealer commented during the 60-day period. The dealer supported: Removing the need to send a form to local law enforcement. Modernizing the form, including allowing digital signatures. Accepting photo IDs instead of a 2-inch by 2-inch photograph. Ending the fingerprint requirement for each application. ATF responded positively. The agency said all NFA forms are being updated and moved to electronic versions. Electronic signatures and fillable forms are becoming available. ATF plans to have all forms online by 2026. How to Comment ATF is accepting public comments about these changes until December 1, 2025. Comments can be sent online at www.reginfo.gov/public/do/PRAMain by searching for the title or OMB control number 1140-0015. For more information, contact Meghan Tisserand at the National Firearms Act Division, or Darwin Arceo at the Department of Justice. Dated: October 28, 2025 Source: Federal Register, Volume 90, Number 208, Pages 48903–48904. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Denies Registration for MCRGC, LLC to Grow Marijuana Estimated reading time: 5–7 minutes Background On May 7, 2024, the DEA sent an Order to Show Cause to MCRGC, LLC. This order explained that MCRGC, LLC’s application to grow marijuana might be denied because it did not meet certain legal requirements. Reasons for Denial The DEA found that MCRGC, LLC did not have: A physical location where it could grow marijuana and that the DEA could inspect. A DEA Schedule I researcher certificate of registration for marijuana. A real supply agreement with a registered DEA Schedule I researcher who has an approved research plan. A complete and accurate application as required. Hearing Process MCRGC, LLC was told it could ask for a hearing about its application. The DEA mailed and emailed the Order to Show Cause to the company. MCRGC, LLC replied to the email but did not ask for a hearing within 30 days. Because of this, the company was considered in default. This means that the DEA viewed all the facts in the Order as true. Legal Standards The law says that the DEA can only give registration to grow controlled substances like marijuana if doing so is consistent with the public interest. The DEA must also follow treaty obligations and make sure there are controls to prevent illegal use or theft. Rules require that the DEA can inspect where the drugs would be made. For marijuana, there are extra criteria, including having proper researcher registration and supply agreements. Findings Because MCRGC, LLC did not respond in time, its admission that it had no physical facility, no researcher registration, no supply contract, and an incomplete application was accepted. The DEA reviewed the facts and found that approving the application would not be in the public interest. Order and Authority The DEA Administrator officially denied the application from MCRGC, LLC. Any other applications from the company to grow marijuana are also denied as of November 20, 2025. Document Details This decision was signed by DEA Administrator Terrance Cole on October 9, 2025. The document was filed and made official by Heather Achbach, the DEA Federal Register Liaison Officer. The Federal Register published this notice on October 21, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Dr. James Orrington II’s Right to Handle Controlled Substances Estimated reading time: 5 minutes The Drug Enforcement Administration (DEA) has revoked the registration of Dr. James Orrington II, D.D.S., of Chicago, Illinois. This action means Dr. Orrington can no longer handle controlled substances in the state of Illinois. The DEA sent an Order to Show Cause to Dr. Orrington on May 23, 2025. The order said he was not allowed to handle controlled substances in Illinois. The order also warned that if he did not respond, he would lose his right to a hearing. Dr. Orrington did not answer the order or ask for a hearing. This means he is in default. The DEA explained how they tried to contact Dr. Orrington. First, they tried to call him and visit his address. When these steps failed, they mailed the order to his address. The mail was not returned. Then, they emailed the order to him. That email was also not returned. Because none of these attempts failed, the DEA said Dr. Orrington was given enough notice. According to the facts, Dr. Orrington’s Illinois dental and controlled substance licenses were suspended on May 23, 2024. The DEA checked online records and confirmed that his licenses remain suspended. This means Dr. Orrington is not allowed to practice as a dentist or handle controlled substances in Illinois. The law says a dentist must have a valid state license to handle these substances. The Controlled Substances Act requires practitioners to have state authority. Since Dr. Orrington’s licenses are suspended, he does not meet this rule. The DEA cited laws and past cases to support its decision. According to 21 U.S.C. 824(a)(3), the Attorney General can revoke a registration if a state license is suspended. Illinois law defines who can dispense controlled substances, and Dr. Orrington is not currently authorized to do so. Because his licenses are not active, Dr. Orrington cannot keep his DEA registration. The DEA’s final order says Dr. Orrington’s registration number BO7484811 is revoked. Any requests by Dr. Orrington to renew, change, or add new registrations in Illinois are also denied. This order takes effect on November 19, 2025. The order was signed by DEA Administrator Terrance Cole on October 9, 2025. The official document was filed for publication in the Federal Register by the DEA Federal Register Liaison Officer, Heather Achbach. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Dr. Abolghasem Rezaei’s Registration to Handle Controlled Substances in Oklahoma Estimated reading time: 1–7 minutes On October 20, 2025, the U.S. Drug Enforcement Administration (DEA) announced that it is revoking the Certificate of Registration No. FR0228747 for Dr. Abolghasem Rezaei of Lawton, Oklahoma. The decision was published in the Federal Register, Volume 90, Number 200. Order to Show Cause Issued On May 22, 2025, the DEA issued an Order to Show Cause (OSC) to Dr. Rezaei. The OSC stated that Dr. Rezaei was “currently without authority to prescribe, administer, dispense, or otherwise handle controlled substances in the State of Oklahoma.” This was the state where Dr. Rezaei was registered with the DEA. Dr. Rezaei was informed of his right to request a hearing. He did not file a request, and as a result, the DEA considered him to be in default. This meant that he admitted to the factual claims in the OSC. Oklahoma License Suspended The facts listed in the OSC proved that on December 5, 2024, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBNDD) suspended Dr. Rezaei’s OBNDD registration. On February 13, 2025, the OBNDD upheld the suspension. Oklahoma online records confirmed Dr. Rezaei’s OBNDD registration is inactive. This means he is not allowed to handle controlled substances in Oklahoma. Legal Requirements for Registration Federal law, under 21 U.S.C. 824(a)(3), says the DEA can revoke a registration if the state’s license is suspended or revoked. For a medical practitioner to have a DEA registration, they must have state authority to dispense controlled substances. Oklahoma law requires every person who dispenses, prescribes, or uses controlled substances in the state to have an OBNDD registration. Dr. Rezaei’s registration is not active, so he cannot handle controlled substances. Final Decision and Order Based on these facts, the DEA found that Dr. Rezaei is not authorized to handle controlled substances in Oklahoma. Because of this, he cannot keep his DEA registration. Dr. Rezaei’s DEA Certificate of Registration No. FR0228747 is revoked. Any pending applications by Dr. Rezaei to renew or modify this registration are also denied. Any other pending applications for registration in Oklahoma are also denied. Effective Date This order is effective as of November 19, 2025. Authority The official decision was signed on October 9, 2025, by DEA Administrator Terrance Cole. The document was prepared for publication by Heather Achbach, Federal Register Liaison Officer, Drug Enforcement Administration. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Denies Registration Application of Dr. Ali Elhorr Estimated reading time: 4–6 minutes On October 20, 2025, the Drug Enforcement Administration (DEA) published a decision to deny Dr. Ali Elhorr’s application for a DEA Certificate of Registration. Dr. Elhorr is a physician from Dearborn, Michigan. Reasons for Denial Dr. Elhorr’s application was denied for two main reasons: Mandatory Exclusion from Federal Health Programs: Dr. Elhorr was found to be excluded from Medicare, Medicaid, and all Federal health care programs. This exclusion began on February 20, 2017, for a minimum of 15 years. The exclusion was issued by the U.S. Department of Health and Human Services, Office of Inspector General, after Dr. Elhorr pled guilty to health care fraud in 2016. Material Falsification of DEA Application: On October 19, 2022, Dr. Elhorr applied for a DEA registration to prescribe controlled substances. The application asked if he had ever been excluded from Medicare or state health programs. Dr. Elhorr answered “No.” At the time, he was already excluded from these programs. The DEA found this to be a false statement and a violation of the Controlled Substances Act. Procedural Details Dr. Elhorr was personally served an Order to Show Cause (OSC) on June 3, 2025. He was informed that he could request a hearing. The DEA did not receive any response or request for a hearing from Dr. Elhorr. This counted as a default, meaning Dr. Elhorr was found to admit to all facts in the OSC. Legal Findings The DEA reviewed all evidence. The agency decided that Dr. Elhorr: Was mandatorily excluded from federal programs. Falsified his DEA application when he answered “No” to being excluded. Did not accept responsibility for these actions since he did not respond to the OSC. Each of these reasons, by themselves, was enough for the DEA to deny his application. Importance of Compliance The DEA stated that strict rules are important for controlling drugs and fighting drug abuse. Allowing someone who did not follow the rules to receive a registration would send a wrong message. Final Order The DEA denied Dr. Elhorr’s application for DEA registration, as well as any other pending applications in Michigan. This order is effective as of November 19, 2025. Official Signatures The document was signed by Administrator Terrance Cole on October 9, 2025. The notice was officially published by the Federal Register Liaison Officer of the DEA, Heather Achbach. References This news post is based on Federal Register Volume 90, Number 200 (Monday, October 20, 2025), pages 48375-48378. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Registrations of Dr. Chantal F. Nouvellon, D.O. Estimated reading time: 4 minutes The Drug Enforcement Administration (DEA) has revoked the Certificates of Registration for Dr. Chantal F. Nouvellon, D.O. The decision was announced in the Federal Register on October 20, 2025. On April 2, 2025, the DEA issued an Order to Show Cause to Dr. Nouvellon. The DEA proposed revoking her DEA registrations, BN5595775 and FN5439016. The reason was that Dr. Nouvellon no longer had authority to handle controlled substances in Massachusetts and New Hampshire. These are the states where she was registered with the DEA. The Order to Show Cause told Dr. Nouvellon she could ask for a hearing. She did not request a hearing. The DEA decided she was in default. By regulation, default means she gave up her right to a hearing and admitted the facts in the DEA’s order. The DEA served the order by email to Dr. Nouvellon’s attorney and later directly to her. Dr. Nouvellon responded by saying she was not prescribing since her suspension. There was no further response from her. According to the DEA, Dr. Nouvellon’s Massachusetts medical license was suspended on October 17, 2024. Online records show her Massachusetts license is still suspended. The DEA also found that her New Hampshire license was suspended on December 20, 2024, and it remains suspended. Because Dr. Nouvellon is not licensed in either state, she cannot practice medicine or handle controlled substances there. The rules say a doctor must have state authority to handle controlled substances. Without a valid state license, a doctor cannot have a DEA registration. Massachusetts law defines a “practitioner” as a person registered to handle controlled substances in the state. New Hampshire law says that only a properly licensed practitioner may prescribe, administer, or dispense controlled drugs. With both state licenses suspended, Dr. Nouvellon is not allowed to handle controlled substances in either state. As a result, her DEA registrations for those states have been revoked. The order, signed by DEA Administrator Terrance Cole, also denies any pending applications for Dr. Nouvellon to renew or change her DEA registrations. It also denies any new applications for registration in Massachusetts or New Hampshire. The order takes effect on November 19, 2025. The order was processed according to DEA procedures and published for official record. Source: Federal Register, Volume 90, Number 200, October 20, 2025, Pages 48378-48379. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Registration of Cincinnati Nurse Practitioner for False Fee Exemption Claim Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA) has revoked the DEA registration for Grace S. Joanita, N.P., a nurse practitioner based in Cincinnati, Ohio. The action was taken after Ms. Joanita was found to have provided false information on her DEA registration renewal application. Background on the Case On December 7, 2021, Ms. Joanita submitted a renewal application for her DEA registration number MJ5209677. The application included questions about whether she qualified for an exemption from paying the registration fee. On the form, Ms. Joanita listed a certifying official and claimed a fee exemption. An investigation found that Ms. Joanita had not worked for the named certifying official since November 20, 2019. This meant that her claim for fee exemption was false at the time she filed her renewal application. Because of her answers on the application, her registration was renewed without payment of the required fee. Opportunities to Correct the Filing The DEA contacted Ms. Joanita in December 2021, January 2022, and August 2022. They provided her the opportunity to pay the required registration fee and to fill out a form regarding any changes to her fee exemption status. At the time the Order to Show Cause (OSC) was issued, Ms. Joanita had neither paid the fee nor submitted the required update form. Legal Process and Default On February 6, 2023, the DEA sent Ms. Joanita an Order to Show Cause, proposing to revoke her DEA registration. She was informed of her right to request a hearing and answer the allegations. Ms. Joanita did not request a hearing, file an answer, or respond to the OSC in any way. The DEA determined that Ms. Joanita was therefore in default and that she had admitted to the factual allegations made in the OSC. The facts in the OSC were accepted as the basis for the Agency’s decision. Findings The DEA found that Ms. Joanita: Submitted a false statement on her renewal application by naming a certifying official she no longer worked for. Claimed fee exemption status when she was not entitled to it. Did not pay her registration fee as required by law and regulations. Did not respond to written requests or correct her application when given a chance. Material Falsification The DEA explained that providing false information on a renewal application is a serious violation. False statements about fee exemption are considered material because they affect the DEA’s decision to grant or renew a registration. The government’s evidence was found to be clear and convincing. The Agency decided it met the legal standard needed to prove that Ms. Joanita materially falsified her application. Sanctions and Final Order When someone is found to have submitted a materially false application, the burden shifts to them to show they can be trusted with DEA registration. Ms. Joanita did not respond or accept responsibility for the violation. The DEA stated that allowing a registrant to keep their registration after making false statements would send the wrong message. The Agency said that they must enforce the laws and require honest applications. As a result, the DEA issued an order: Revoking DEA Certificate of Registration No. MJ5209677 for Grace S. Joanita, N.P. Denying any pending applications for renewal or modification of this registration. Denying any other pending applications for additional registration in Ohio from Ms. Joanita. Order Effective Date This order is effective November 17, 2025. The order was signed by Administrator Terrance Cole of the Drug Enforcement Administration on October 1, 2025. The document was published in the Federal Register by Heather Achbach, DEA Federal Register Liaison Officer. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Grants Registration to Dr. Shannon Wagner After Review Estimated reading time: 7–9 minutes On October 17, 2025, the Drug Enforcement Administration (DEA) announced its decision in the case of Dr. Shannon Wagner, D.O., from Green Bay, Wisconsin. Dr. Wagner had applied for a DEA Certificate of Registration, which allows doctors to prescribe certain medicines. The Government had given Dr. Wagner an Order to Show Cause on August 13, 2024. This means the government asked Dr. Wagner to explain why they should not deny her application. The Government said Dr. Wagner had been excluded from all federal health care programs, like Medicare and Medicaid, under 42 U.S.C. 1320a-7(a). There was a hearing before DEA Administrative Law Judge Teresa A. Wallbaum. She gave her decision on February 21, 2025, and said Dr. Wagner’s application should be granted. The DEA reviewed the whole record and agreed with the judge. Background and Events On August 21, 2014, in a Michigan federal court, Dr. Wagner pleaded guilty to conspiracy to pay and receive health care kickbacks and to filing a false tax return. Based on these crimes, the Department of Health and Human Services (HHS) excluded her from all federal health care programs for 13 years, starting from December 18, 2014. This exclusion will end in 2027. The DEA found clear proof that Dr. Wagner is currently excluded from these programs. The law lets the DEA deny a registration if the person is excluded from federal health care programs. Dr. Wagner’s Response Dr. Wagner admitted to her mistakes. She said her actions were wrong and took the blame for her crimes. She said she should have stopped the illegal activity and accepted responsibility for everything, including not stopping her husband’s actions when he managed their business. Dr. Wagner also said she learned important lessons while in prison and working other jobs after her release. She worked as a waitress, delivery driver, cleaner, and more. She said these jobs humbled her and made her understand how important her medical license was. To get her medical license back in Wisconsin, Dr. Wagner worked under a limited license for a year with regular reports to the Wisconsin Medical Board. After that, she got her full license. She also took about 240 hours of continuing medical education credits, much more than the state’s minimum. Dr. Wagner is making monthly restitution payments and intends to pay off the full amount of $270,000. Remedial Measures Dr. Wagner is not married to her co-conspirator anymore. The ALJ and the DEA said that this and her actions after prison showed she took steps to make sure her crimes would not happen again. She now plans to use her medical skills to help people in prison. Other Factors The DEA said Dr. Wagner’s crimes were very serious. She was part of a seven-year health care fraud conspiracy and filed a false tax return. She spent 17 months in prison, served supervised release, lost property, and has been making consistent restitution payments. Her criminal conduct ended over 13 years ago. The DEA said Dr. Wagner’s punishment and state licensing actions were enough to prevent her from doing wrong again and to deter others. The DEA said denying her application was not needed as more punishment. Final Decision The DEA found that Dr. Wagner could be trusted with a DEA registration. She accepted responsibility, took real steps to correct her behavior, and showed insight into her past crimes. The DEA granted her application for a DEA Certificate of Registration. This order is effective immediately. The decision was signed by DEA Administrator Terrance Cole on October 1, 2025, and published in the Federal Register. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Hovic Pharmacy’s Controlled Substance Registration After Violations Estimated reading time: 5–7 minutes Background On October 20, 2021, the DEA issued an Order to Show Cause (OSC) against Hovic Pharmacy. The DEA wanted to revoke the pharmacy’s registration number FH5569112. The DEA said that Hovic’s continued registration would not be in the public interest. The case focused on Hovic Pharmacy’s filling of controlled substance prescriptions. The prescriptions were often filled outside the usual course of pharmacy practice. The pharmacy did not follow its “corresponding responsibility” under federal rules and Texas law. Investigations and Findings DEA presented evidence from an independent pharmacy expert and several declarations. The expert found multiple “red flags” in prescription data. These red flags showed a risk of drug abuse and diversion for illegal street sales. A person known as “Recruiter” was at the center of the scheme. Recruiter pled guilty to conspiracy to dispense and distribute hydrocodone. Recruiter’s declaration showed that the scheme ran from at least 2017 to 2020. Recruiter recruited others to act as patients. They got controlled substance prescriptions from doctors, then filled them at Hovic. Recruiter picked up the drugs, forging patient signatures or signing their own name. The drugs were then sold on the street. Hovic Pharmacy’s staff rarely questioned the prescriptions. The staff did not ask for identification or proof of authority for pick-up. Hovic’s pharmacists even told Recruiter how to pick up drugs for others and suggested signing the signature log with fake or real names. One pharmacist lent Recruiter up to $800 to pay for doctor visits, expecting to be repaid after street sales. Expert Review Dr. Diane Ginsburg, a registered pharmacist and expert, reviewed the government’s evidence. She explained that pharmacy law requires pharmacists to catch and resolve red flags before filling prescriptions for dangerous drugs. These drugs included hydrocodone, alprazolam, carisoprodol, and promethazine with codeine. Dr. Ginsburg found that Hovic’s staff did not try to resolve red flags and did not document consultations as required by law. Hovic Pharmacy filled about 138 prescriptions with combinations of these drugs, called “cocktails.” These cocktails are known to be high-risk for abuse. The pharmacy also filled monthly or repeated prescriptions for promethazine with codeine for three people, which is a red flag for abuse. The pharmacy filled many prescriptions from doctors who issued the same or similar prescriptions to different people, known as “pattern prescribing.” Hovic filled these without investigating the red flags. Some individuals also used “pharmacy shopping,” getting controlled substances at multiple pharmacies, including Hovic. Again, Hovic failed to resolve the red flags. Over eighteen months, Hovic Pharmacy released about 13,135 controlled substance tablets and about a 3,478 days’ supply of promethazine with codeine into the community. These drugs are commonly abused and frequently diverted. Legal Standards and Violations Federal law says a prescription for a controlled substance must be for a legitimate medical purpose. Both the prescribing doctor and the pharmacist have responsibilities. Texas law also sets standards and requires pharmacists to identify and resolve red flags. Written records are required for consultations with doctors about prescriptions. The DEA determined that Hovic Pharmacy broke both federal and Texas laws. The pharmacy failed to resolve questions about prescriptions and released large amounts of dangerous drugs into the community. This included filling prescriptions for known street dealers, filling prescriptions for others based on forged signatures, and failing to follow professional standards. Sanction Hovic Pharmacy did not show up for its scheduled hearing and presented no evidence in its defense. The DEA found that Hovic did not show any responsibility for its actions or offer any plan to prevent future issues. The DEA found that allowing Hovic to keep its registration would not protect the public. Based on the evidence, the DEA revoked Hovic Pharmacy’s certificate of registration. The DEA also denied any pending application by Hovic for renewal or modification of registration in Texas. The revocation takes effect on November 17, 2025. The DEA stressed the need to maintain trust and safety in the pharmacy community. The decision aims to deter similar conduct by others. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Denies Registration Application of David S. Pecora, P.A. Estimated reading time: 3–5 minutes On October 17, 2025, the Drug Enforcement Administration (DEA) announced the denial of an application for DEA controlled substances registration submitted by David S. Pecora, P.A., of Bemidji, Minnesota. The application control number was W23054133M. Reasons for Denial The DEA denied Mr. Pecora’s application because he was found to have made false statements on five DEA registration applications, including the most recent application in May 2023. The agency also found that granting registration to Mr. Pecora would not be in the public interest. Default in Proceedings Mr. Pecora was notified of the allegations and given a chance to respond. He did not request a hearing, submit an answer, or respond. Because of this, the DEA determined he was in default. By default, he was also considered to have admitted to the facts stated in the notice. Materially False Applications The DEA determined that Mr. Pecora submitted applications with answers that were false or incomplete. On earlier applications, he answered “no” to questions about past suspensions or denials of state professional licenses, when in fact: In July 2007, his West Virginia registered nursing license was suspended. In October 2008, his Florida registered nursing license was suspended. In July 2012, his application for a physician assistant license in North Dakota was denied. His Minnesota physician assistant license was suspended and reinstated several times between 2014 and 2023. He also failed to truthfully report if he ever surrendered a DEA registration for cause. Repeated False Answers On his applications from January 2012, October 2013, January 2016, February 2020 (renewal), and May 2023, Mr. Pecora did not disclose all adverse actions taken against his medical and nursing licenses or his previous surrenders of DEA registrations. The DEA found these omissions and false statements to be material, which means they were important for making a decision on whether to grant or deny a registration. Findings About Controlled Substance Abuse and Diversion The DEA record shows: In 2007, Mr. Pecora was addicted to zolpidem, a controlled substance, and underwent addiction treatment. In 2013, while being monitored for drug abuse, he wrote prescriptions for carisoprodol (Soma) for two volleyball teammates, in return for some of the pills for his own use. He ordered carisoprodol online for personal use while in addiction treatment. He tested positive without a prescription for carisoprodol. In November 2020, Mr. Pecora stole propofol, another controlled substance, from an operating room for personal use. Public Safety and DEA Standards The DEA found that Mr. Pecora’s actions included diverting controlled substances for himself by fraudulent prescriptions and theft. He demonstrated a lengthy history of substance abuse and failed to comply with controlled substances laws. Under the Controlled Substances Act, the DEA must deny a registration if granting it would not be in the public interest. The agency found Mr. Pecora’s conduct threatened public health and safety. Sanction and Final Decision Mr. Pecora’s failure to respond was considered a lack of acceptance of responsibility for his actions. The DEA concluded he could not be trusted with a DEA registration. Therefore, the DEA denied his application for registration. The denial also affects any other pending applications from Mr. Pecora for registration in Minnesota. The order is effective as of November 17, 2025. Document Signed This decision was signed by DEA Administrator Terrance Cole on October 1, 2025. Heather Achbach, Federal Register Liaison Officer, confirmed the publication. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Receives Membership Update from OpenGMSL Association Estimated reading time: 3–5 minutes The U.S. Department of Justice has announced an update related to the OpenGMSL Association. This update was published in the Federal Register on October 3, 2025. On September 22, 2025, OpenGMSL Association filed written notifications with the Attorney General and the Federal Trade Commission. These notifications are required under Section 6(a) of the National Cooperative Research and Production Act of 1993. This law helps limit the recovery of antitrust plaintiffs to actual damages in certain situations. The update lists new members that have joined the OpenGMSL Association. The new members are: Alfamation, an InTest Company, Lissone, Italy Analog Devices Inc., Wilmington, MA ASTRODESIGN, Inc., Tokyo, Japan Beijing ESWIN Computing Technology Co., Ltd., Beijing, People’s Republic of China Core Microelectronics, Sariyer, Turkey Granite River Labs, Santa Clara, CA Murata Manufacturing Co., Ltd., Kyoto, Japan Qualcomm Incorporated, San Diego, CA ROHM Co., Ltd., Kyoto, Japan Rsemi Zhiyuan (Hangzhou) Semiconductor Science and Technology Limited Company, Hangzhou City, People’s Republic of China Samsung Electronics, Hwaseong-si, Republic of Korea SmartSens Technology (Shanghai) Co., Ltd., Shanghai, People’s Republic of China TDK Corporation, Tokyo, Japan Valeo Comfort and Driving Assistance, Creteil, France No other changes have been made to the group’s membership or planned activities. The OpenGMSL Association states that membership remains open. The association plans to file more notifications for any future changes in membership. The original notification about this group was filed on June 30, 2025. It was published in the Federal Register on August 13, 2025, under entry 90 FR 38998. This update was formally published by Suzanne Morris, Deputy Director for Civil Enforcement Operations at the Antitrust Division of the Department of Justice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes to Regulate P2P Methyl Glycidic Acid as a List I Chemical Estimated reading time: 4–8 minutes The Drug Enforcement Administration (DEA) has proposed a new rule. The rule would make P2P methyl glycidic acid, also called 2-methyl-3-phenyloxirane-2-carboxylic acid or BMK glycidic acid, a List I chemical. This chemical and its different forms are used to make illegal drugs such as methamphetamine and amphetamine. Background of the Chemical P2P methyl glycidic acid is an important chemical for making schedule II drugs like phenyl-2-propanone (P2P), methamphetamine, and amphetamine. People in illegal labs use this chemical to make these drugs. The DEA has found that this chemical does not have any legal or industrial use, other than for research or laboratory tests in small amounts. Reports have shown that large amounts of P2P methyl glycidic acid and its salts are being made and shipped internationally, mainly from China and mostly seized in the Netherlands. Over 47 metric tons of the sodium salt and 51 metric tons of the acid have been seized since 2012. Reason for the Rule The United Nations added P2P methyl glycidic acid and its esters to its international drug control list in 2024. This means the United States is required to take action to control this chemical. By creating this rule, the DEA is meeting its obligations under the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Details of the Proposed Rule All forms of P2P methyl glycidic acid will be regulated, including its: Esters Optical and geometric isomers Salts Salts of its isomers and esters Any chemical mixture containing even a small amount of P2P methyl glycidic acid will be controlled. There will be no set minimum amount (threshold) for regulation. All amounts will be covered by the rules. Registration and Compliance Anyone who handles this chemical—manufacturers, distributors, importers, or exporters—must register with the DEA. Separate registrations are needed for different activities and locations. There is a process for temporary exemption while registration is being processed, as long as an application is submitted within 30 days after the final rule is published. Warehouses that only store the chemical for DEA-registered businesses do not need to register, but they cannot distribute the chemical to others without registration. Recordkeeping and Reporting DEA registrants must keep records and make reports of every transaction involving P2P methyl glycidic acid. These records must be kept for two years. Bulk manufacturers must file annual reports on manufacturing, inventory, and use. Any strange or suspicious transactions, losses, or thefts must be reported to the DEA. Import and Export Controls Importing and exporting P2P methyl glycidic acid will require following DEA rules and regulations. Security and Inspections Registrants must provide security to prevent theft or diversion of the chemical. The DEA can inspect places where the chemical is handled or stored. Impact and Costs The DEA states there is little to no legal use for P2P methyl glycidic acid in the United States. Any possible costs will be only for registration fees, mainly for businesses who choose to keep handling the chemical. Nine businesses have been found to offer the chemical, but actual sales likely are small. Costs to these businesses are expected to be minimal. Public Comments The DEA is asking for public comments. Comments must be submitted by November 3, 2025. Comments can be made online at https://www.regulations.gov by looking up Docket No. DEA-1395. Legal References If the rule becomes final, handling P2P methyl glycidic acid without DEA approval will be illegal. Civil, criminal, and administrative penalties can apply. How to Learn More For more information or questions, people can contact Terrence L. Boos at the DEA’s Drug and Chemical Evaluation Section by phone at (571) 362-3249. The full proposed rule is available at http://www.regulations.gov. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Federal Bureau of Investigation Seeks Comments on ViCAP National Crime Database Information Collection Estimated reading time: 5–10 minutes The Department of Justice (DOJ), Federal Bureau of Investigation (FBI), Critical Incident Response Group (CIRG), is submitting an information collection request to the Office of Management and Budget (OMB). This request is in line with the Paperwork Reduction Act of 1995. Comments are being accepted for 30 days, until October 27, 2025. If you have comments about the time it will take to respond, how the collection is done, or suggestions to improve it, you can contact Nathan Graham, Program Manager at the FBI Academy in Quantico, Virginia. The phone number is (703) 632-4309. The proposed collection was previously published for a 60-day comment period on September 17, 2025. The FBI welcomes written comments and suggestions on: If the collection of information is necessary. The accuracy of the estimated burden to the public. How to improve the quality and clarity of the information. Ways to reduce the burden, including electronic methods. Written comments and recommendations should be submitted within 30 days of the notice. They must be submitted at www.reginfo.gov/public/do/PRAMain. Use “Currently under 30-day Review—Open for Public Comments” or search “OMB Control Number 1110-0011” to find the request. The DOJ seeks approval for this information collection for three years. OMB cannot authorize for more than three years without another review. Details about the Collection ViCAP is a unit of the FBI that analyzes serial violent and sexual crimes. The ViCAP National Crime Database is the largest collection of major violent crime case data in the United States. It gathers data about the following: Homicides (and attempts) believed to be part of a series, random, or sexually oriented. Sexual assaults suspected to be part of a series or committed by a stranger. Missing persons cases that suggest foul play and the person is still missing. Unidentified human remains where the death is known or suspected to be homicide. Overview of the Information Collection This is a revision of a previously approved collection. The collection is named “ViCAP National Crime Database.” There is no specific agency form number. The respondents are state, local, and tribal governments. Participation is voluntary. There are an estimated 5,700 respondents. The estimated time per respondent is 20 minutes. Users decide how often to respond, but for calculation, it is counted as once per year. The total estimated annual time burden is 1,900 hours. There are no other annual costs. For more information, contact Darwin Arceo at the Department of Justice, at 145 N Street NE, 4W-218, Washington, DC 20530. This information was published in the Federal Register on September 26, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

FBI Releases Notice on Revised Friction Ridge Card Data Collection Estimated reading time: 3–5 minutes The Federal Bureau of Investigation (FBI) has announced a proposed change to its approved collection of friction ridge card data. This change was shared in the Federal Register on September 17, 2025. The public can comment on it for 60 days until November 17, 2025. The FBI collects and keeps fingerprint and palm print records using special forms. These records help law enforcement and government agencies identify people and keep records about criminal events. Details of the Collection The collection includes several forms: FD-249: Arrest and Institution FD-258: Applicant FD-1164: Identity History Summary Request FD-884: FBI Standard Palm Print FD-884a: Supplemental Finger and Palm Print FD-1212: Voluntary Appeal File Fingerprint FD-1211: Firearm-Related Challenge Fingerprint FD-1222: Restoration of Federal Firearm Rights These forms are for law enforcement groups and civil groups that need security checks or background checks. The record data is kept in the FBI’s Next Generation Identification System (NGI). Purpose of the Collection The FBI collects this information under Title 28, United States Code, Section 534. This law lets the FBI gather, keep, and share identification records, including for criminal and other investigations. The forms make sure the FBI can help other agencies across the country. Statistics and Burden The expected number of respondents each year is 459,238. Each response is estimated to take 10 minutes. The total yearly burden is about 12.4 million hours. The total annual cost for this collection is $0. Feedback and Questions People can send comments about: If collecting this information is needed. If the estimated time and process are correct. Ways to make the collection better or clearer. How to make it easier for people to submit information, including electronic ways. For more information or to give feedback, contact Brian A. Cain at the FBI’s Criminal History Information and Policy Unit in Clarksburg, West Virginia. You can call 304-625-5590 or email the office. For other details, contact Darwin Arceo at the U.S. Department of Justice in Washington, D.C. This notice was shared by Darwin Arceo, Department Clearance Officer for the Paperwork Reduction Act, U.S. Department of Justice, on September 15, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.